首页> 外国专利> IMMUNOGENIC MODULATION BY ENDOCRINE DEPRIVATION THERAPY IMPROVES SENSITIVITY OF TUMOR CELLS TO IMMUNE MEDIATED LYSIS

IMMUNOGENIC MODULATION BY ENDOCRINE DEPRIVATION THERAPY IMPROVES SENSITIVITY OF TUMOR CELLS TO IMMUNE MEDIATED LYSIS

机译：内啡肽去除疗法的免疫原性调节可提高肿瘤细胞对免疫介导的裂解的敏感性

页面导航

摘要
著录项
相似文献

摘要

The invention is directed to methods of reducing growth of prostate cancer cells and breast cancer cells, which comprises treating such cancer cells with a combination of androgen or endocrine deprivation therapy (e.g., enzalutamide, abiraterone, and tamoxifen) and immunotherapy.

机译：本发明涉及减少前列腺癌细胞和乳腺癌细胞生长的方法，其包括用雄激素或内分泌剥夺疗法（例如恩杂鲁胺，阿比特龙和他莫昔芬）和免疫疗法的组合来治疗此类癌细胞。

著录项

公开/公告号US2020140567A1

专利类型
公开/公告日2020-05-07

原文格式PDF
申请/专利权人 THE UNITED STATES OF AMERICAAS REPRESENTED BY THE SECRETARYDEPARTMENT OF HEALTH AND HUMAN SERVICES;
展开▼

申请/专利号US201916686390
发明设计人 JEFFREY SCHLOM;JAMES W. HODGE;
展开▼

申请日2019-11-18
分类号C07K16/30;A61K45/06;A61K31/138;A61K31/4166;A61K31/58;A61K39;A61K31/517;A61K39/395;C07K16/28;
国家 US
入库时间 2022-08-21 11:20:10

相似文献

专利
外文文献
中文文献